Financial Reports

Date	Title
June 6, 2022	Add Files Akari Therapeutics 2021 Annual Report 1.2 MB
June 4, 2021	Add Files Akari Therapeutics 2020 Annual Report 873.6 KB
June 1, 2020	Add Files Akari Therapeutics 2019 Annual Report 777.9 KB
June 7, 2019	Add Files Akari Therapeutics 2018 Annual Report 877.1 KB
August 8, 2018	Add Files Akari Therapeutics 2017 Annual Report 6.1 MB
May 15, 2017	Add Files Statutory Accounts Year Ended 31DEC2016 1.4 MB

In severe or life-threatening conditions where there are no available treatment options, regulators may grant permission to provide a treating physician access to an unapproved drug; this is known as expanded access. At this time, the safety and effectiveness of nomacopan to treat diseases such as Atopic Keratoconjunctivitis (AKC), Bullous Pemphigoid (BP); Thrombotic Microangiopathy (TMA), and Paroxysmal Nocturnal Hemoglobinuria (PNH) has not been established. Until more data are available, Akari Therapeutics is not considering requests for expanded access outside of clinical trials. This policy may change as safety and efficacy are better demonstrated. For questions regarding our current expanded access policy, please contact Akari Therapeutics at +44 (0)20-8004-0261.

Akari TX

Financial Reports

Financial Reports

LONDON

NEW YORK

EXPANDED ACCESS POLICY

Skip links

Financial Reports

Financial Reports

Footer

LONDON

NEW YORK

EXPANDED ACCESS POLICY